The Effect of Laparoscopic Sleeve Gastrectomy on Blood Phoenixin-14 Levels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

36 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-07-01

Study Completion Date

2025-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Obesity is a major global health concern with a rising prevalence and numerous associated comorbidities. For the treatment of severe obesity, bariatric surgery stands as the most effective procedure. Bariatric and metabolic surgical procedures are applied even in the absence of comorbidities, particularly in patients with Type-III obesity and above. Currently, the most commonly performed bariatric metabolic surgical procedures are Laparoscopic Sleeve Gastrectomy (LSG) and Roux-en-Y gastric bypass.

Animal studies have shown that phoenixin (PNX) in the paraventricular, arcuate, and solitary tract nuclei contributes to regulating food intake, and its intracerebral administration in rats increased food intake.

The aim of this study is to investigate whether PNX-14 levels change before and after LSG in patients undergoing the procedure for severe obesity, given the potential association of PNX-14 with obesity and insulin resistance through its influence on the appetite center in metabolism.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Istmin Levels in Laparoscopik Sleeve Gastrectomy

NCT07335549

Obesity & Overweight Sleeve Gastrectomy Adipokines

COMPLETED

Pan Immune Inflammation Value for Perioperative Complications of Laparoscopic Sleeve Gastrectomy

NCT06284356

Morbid Obesity Laparoscopic Sleeve Gastrectomy Post Operative Complicaiton

COMPLETED

Body Mass Index and Obesity Surgery Mortality Risk Score in Perioperative Complications of Laparoscopic Sleeve Gastrectomy

NCT04427644

Perioperative Complication Laparascopic Sleeve Gastrectomy BMD +3 more

COMPLETED

Anesthetics and Cerebral Oxygenation in LSG

NCT03946657

Morbid Obesity Bariatric Surgery Candidate Anesthesia

COMPLETED PHASE4

Weight Loss and Aggression

NCT05654584

Obesity Obesity, Morbid Aggression

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Introduction Obesity is a major global health concern with a rising prevalence and numerous associated comorbidities. In 2022, approximately 2.5 billion adults (aged 18 and over) were overweight (BMI between 25 kg/m² and 30 kg/m²), with 890 million of them categorized as obese (BMI ≥ 30 kg/m²).

For the treatment of severe obesity, bariatric surgery stands as the most effective procedure. Bariatric and metabolic surgical procedures are applied even in the absence of comorbidities, particularly in patients with Type-III obesity and above. Various bariatric metabolic surgical techniques have been developed for this purpose. Currently, the most commonly performed bariatric metabolic surgical procedures are Laparoscopic Sleeve Gastrectomy (LSG) and Roux-en-Y gastric bypass.

Animal studies have shown that phoenixin (PNX) in the paraventricular, arcuate, and solitary tract nuclei contributes to regulating food intake, and its intracerebral administration in rats increased food intake. A study by Cundubey et al. in women with polycystic ovary syndrome (PCOS) demonstrated significantly increased serum PNX-14 levels in obese PCOS patients. PNX is not only expressed and secreted by the central nervous system but also by peripheral tissues such as the heart, adipose tissue, pancreas, and stomach. This suggests that PNX-14 plays a crucial role in appetite regulation and energy intake control via the central nervous system.

The aim of this study is to investigate whether PNX-14 levels change before and after LSG in patients undergoing the procedure for severe obesity, given the potential association of PNX-14 with obesity and insulin resistance through its influence on the appetite center in metabolism.

Material-Methods This study is designed as a cross-sectional prospective study. The goal is to include patients who present to the General Surgery Clinic at Elazığ Fethi Sekin City Hospital for severe obesity and are scheduled for Laparoscopic Sleeve Gastrectomy (LSG) as their primary surgery.

In addition to routine pre-operative blood tests, 5 ml of blood will be collected from patients. Another 5 ml will be collected in yellow-capped biochemistry tubes along with routine complete blood count measurements taken for post-operative control. The study will analyze plasma phoenixin-14 (PNX-14) levels both before and after the surgery.

Using the G\*power 3.10 program for repeated measures t-tests, a sample size of at least 36 patients was determined to be appropriate to achieve 90% power with an alpha error probability of 0.05 and a medium Cohen's effect size.

Hypotheses H0 (Null Hypothesis): There is no relationship between LSG performed for severe obesity and the change in pre-operative and post-operative plasma phoenixin-14 (PNX-14) levels.

H1 (Alternative Hypothesis): There is a relationship between LSG performed for severe obesity and the change in pre-operative and post-operative blood PNX-14 levels.

Research Budget The research budget will be covered by the principal investigator. Inclusion Criteria Patients aged 18-65 years. Patients with severe obesity (Body Mass Index (BMI) ≥ 40 kg/m²) with no additional comorbidities (Type III, Type IV, and Type V obesity) who are scheduled for primary LSG.

Patients who consent to participate in the study. Exclusion Criteria Patients who do not consent to participate in the study. Patients scheduled for primary obesity surgery other than LSG (e.g., Single Anastomosis Gastric Bypass, Roux-en-Y Gastric Bypass, Transit Bipartition, Single Anastomosis Sleeve Ileal Bypass, Single Anastomosis Duodeno-intestinal Bypass, Duodenal Switch).

Patients with a BMI ≥ 35 kg/m² with associated medical problems (e.g., Diabetes Mellitus, Asthma, Chronic Obstructive Pulmonary Disease, Ischemic Heart Disease, Hypertension).

Patients with a BMI ≤ 35 kg/m² who do not have a surgical indication. Data Collection Tools/Methods

Patient demographics and anthropometrics: Age, gender, height, body weight, and BMI will be recorded. The severity of obesity will be classified based on BMI values:

BMI = Body Weight (kilograms) / (Height x Height) (meters x meters)

Obesity Severity based on BMI (1,2):

BMI ≥ 18 - \< 25 kg/m² → Normal BMI ≥ 25 - \< 30 kg/m² → Overweight BMI ≥ 30 - \< 35 kg/m² → Class I Obesity BMI ≥ 35 - \< 40 kg/m² → Class II Obesity BMI ≥ 40 - \< 50 kg/m² → Class III Obesity BMI ≥ 50 - \< 60 kg/m² → Class IV Obesity BMI ≥ 60 kg/m² → Class V Obesity Blood PNX-14 Levels: In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected. Another 5 ml will be collected in a yellow biochemistry tube on the 1st post-operative day, in addition to the routine complete blood count for control purposes.

Samples will be centrifuged at 4000 rpm for approximately 10 minutes at the Elazığ Fethi Sekin City Hospital Biochemistry Laboratory and stored at -20 degrees Celsius until the analysis day.

Once all samples are collected, they will be thawed at room temperature and analyzed using the microELISA method with a kit provided by the researchers. The analysis will be performed by Assoc. Prof. Dr. Hakan Ayyıldız at the Elazığ Fethi Sekin City Hospital Biochemistry Laboratory, adhering to the reagent manufacturer's methodology.

Reaction washes will be performed with a Combiwash-Human device, and absorbance measurements will be taken using a Chromate 4300 Microplate Reader (Awareness Technology, Palm City, USA) at 450 nm. Results will be recorded in an Excel sheet containing patient demographic data.

Statistical Method(s) to be Used Data analysis will be performed using IBM Statistical Analysis for Social Sciences (SPSS) version 20 statistical package program. The Shapiro-Wilk test will be used to assess the normality of numerical data distribution. Numerical data will be expressed as mean ± standard deviation (SD) (minimum - maximum values) or median (95% Confidence Interval), depending on their conformity to normal distribution. Categorical data will be presented as numbers (n) and percentages (%).

For comparing plasma PNX-14 levels, either the paired sample t-test or the Wilcoxon Rank test will be used. A pre-operative and post-operative ROC analysis will be conducted to determine a cut-off value for PNX-14 levels. A probability value of p \< 0.05 will be considered statistically significant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity, Morbid Obesity and Overweight

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Selective Laparoscopic Sleeve Gastrectomy Patients

Preoperative and postoperative blood samples obtained from the patients

Preoperative blood sampling for determining Phoenixin 14 levels

Intervention Type DIAGNOSTIC_TEST

In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected.

Postoperative blood sampling for determining Phoenixin 14 levels

Intervention Type DIAGNOSTIC_TEST

In addition to routine blood draws for postoperative controls, 5 ml of blood will be collected.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Preoperative blood sampling for determining Phoenixin 14 levels

In addition to routine blood draws for pre-operative preparations, 5 ml of blood will be collected.

Intervention Type DIAGNOSTIC_TEST

Postoperative blood sampling for determining Phoenixin 14 levels

In addition to routine blood draws for postoperative controls, 5 ml of blood will be collected.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients aged 18-65 years.
* Patients with severe obesity (Body Mass Index (BMI) ≥ 40 kg/m²) with no additional comorbidities (Type III, Type IV, and Type V obesity) who are scheduled for primary LSG.
* Patients who consent to participate in the study.

Exclusion Criteria

* Patients who do not consent to participate in the study.
* Patients scheduled for primary obesity surgery other than LSG (e.g., Single Anastomosis Gastric Bypass, Roux-en-Y Gastric Bypass, Transit Bipartition, Single Anastomosis Sleeve Ileal Bypass, Single Anastomosis Duodeno-intestinal Bypass, Duodenal Switch).
* Patients with a BMI ≥ 35 kg/m² with associated medical problems (e.g., Diabetes Mellitus, Asthma, Chronic Obstructive Pulmonary Disease, Ischemic Heart Disease, Hypertension).
* Patients with a BMI ≤ 35 kg/m² who do not have a surgical indication.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No